Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
المؤلف
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-10، 10ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-08-24
دولة النشر
مصر
عدد الصفحات
10
التخصصات الرئيسية
الملخص EN
Hypoglycemia is the most common side effects for most glucose-lowering therapies.
It constitutes a serious risk that faces diabetic patients who fast during Ramadan (the 9th month in the Islamic calendar).
New glucose-lowering classes like dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 receptor agonist (GLP-1 RA), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are efficacious in controlling blood glucose level with less tendency to induce hypoglycemia and thus may constitute a good choice for diabetic patients during Ramadan.
This study reviews the safety and efficacy of newer glucose-lowering therapies during Ramadan.
This study was accomplished through a careful literature search about studies that assess the benefit and side effects of these new glucose-lowering therapies during Ramadan during September 2015.
Vildagliptin, sitagliptin, liraglutide, exenatide, and dapagliflozin were the only studied glucose-lowering therapies.
All of the studied newer glucose-lowering therapies except dapagliflozin were associated with reduced risk to induce hypoglycemia.
Gastrointestinal upset was common with the usage of liraglutide while increased thirst sensation was common with dapagliflozin.
In conclusion DPP-4 inhibitors such as vildagliptin and sitagliptin may form a suitable glucose-lowering therapy option for Ramadan fasting patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Mudher Mikhael, Ehab. 2016. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research،Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1108221
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Mudher Mikhael, Ehab. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research No. 2016 (2016), pp.1-10.
https://search.emarefa.net/detail/BIM-1108221
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Mudher Mikhael, Ehab. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research. 2016. Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1108221
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1108221
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر